Published
August 12, 2026
LifeMD is a telehealth company that prescribes GLP-1 weight-loss drugs like Wegovy to patients online, and former employees now say clinicians there were pushed to approve prescriptions in about two minutes each. LifeMD strenuously denies it, and there is no class action and nothing for patients to claim.
Allegations Only · No Class Action, Nothing to Claim
This article describes unproven allegations made by former employees and in two lawsuits filed by former company leaders, as reported by STAT. LifeMD strenuously denies them. No court or regulator has found LifeMD liable, no consumer class action over its prescribing practices has been identified, no class has been certified, and there is nothing to claim. This page is informational and is not medical or legal advice.
What Is This About?
On July 20, 2026, the health-news outlet STAT published an investigation reporting that LifeMD, Inc., one of the larger direct-to-consumer telehealth companies prescribing GLP-1 weight-loss drugs, pushed its clinicians to see more patients and issue prescriptions faster while providing little screening and follow-up. The reporting is sourced to five former employees interviewed by STAT and to two lawsuits filed by former senior leaders of the company.LifeMD strenuously denies the allegations. Its chief executive, Justin Schreiber, told STAT that the company's objective "has not been to run a pill mill" and that it has "actually taken the opposite position."
Here is the part readers keep asking about, stated plainly: this is journalism and an employment dispute, not a patient class action. As of August 12, 2026, no consumer class action over LifeMD's GLP-1 prescribing has been identified, no class has been certified, no regulator has announced an enforcement action against the company over these allegations, and there is no claim form or settlement. LifeMD does face a separate securities class action, but that case is about financial guidance given to investors, not about patient care.
Status
Allegations reported — no class action filed
Published July 20, 2026 · five former employees plus two suits by former senior leaders · LifeMD denies the allegations
Central Allegation
Up to 25 patient case reviews per hour
About two minutes per case, based only on intake forms patients filled out themselves · former employees' account, disputed by the company
Can I Claim?
No — there is nothing to claim
No certified class, no settlement, no claim form · this page is informational only
What the Former Employees Allege
The allegations reported by STAT center on the pace of clinical review rather than on any single patient's outcome. According to the former employees, providers were pressed to work faster than they considered clinically responsible. Two of them said clinicians were at times expected to review the cases of 25 people per hour, working only from electronic intake forms the patients had completed themselves. That is roughly two minutes per case, and the workload described included both new patients and refill requests that involved escalating a patient's dose.Former employees also said the company discouraged providers from asking questions the providers considered medically relevant, on the reasoning that extra questions would delay care. The kinds of questions described as discouraged went to patient history, other medical conditions, and screening for eating disorders. A further complaint was structural: patient messages were routed through medical assistants rather than straight to a clinician, which the former employees said could create days-long delays before a reported side effect reached someone qualified to act on it.
Where a Two-Minute Review Runs Out of Road
Obesity medicine is not an unusually complicated field, but it does have a small number of steps that take longer than two minutes and cannot safely be skipped. The accounts collected in the reporting map onto those steps almost exactly, which is what gives them their force. Four checkpoints come up repeatedly.The first is confirming who the patient actually is, physically. A GLP-1 prescription is supposed to rest on a documented weight and body mass index. On an asynchronous platform those numbers arrive as text a patient typed into a form, and nothing in a two-minute file review verifies them. A patient who is not clinically overweight and wants the drug anyway does not have to lie convincingly; they only have to type a number.
The second is bloodwork. Baseline labs — a metabolic panel, thyroid function, HbA1c — exist to catch the conditions that make these drugs risky for a particular person. Former staff said prescriptions were sometimes issued before results came back or before a clinician looked at them, which turns the lab order into a formality rather than a gate.
The third is dose escalation. These medications are deliberately started low and stepped up slowly, because the step-ups are where the serious gastrointestinal, pancreatic, and renal problems tend to surface. The value of that schedule is entirely in the pause between steps, when someone checks whether the patient tolerated the last dose. Former employees described refill queues that were approved in batches, which removes the pause and leaves the schedule as a calendar rather than a clinical decision.
The fourth is what happens when a patient reports that something is wrong. Severe vomiting, dehydration, or abdominal pain that could signal pancreatitis are time-sensitive. If those messages sit in a queue handled by non-clinical staff, the delay is the harm, regardless of how good the eventual answer is.
All four remain allegations. Two of the accounts come from lawsuits filed by former senior leaders — employment disputes between the company and former executives, whose claims have not been tested in court. The rest are interviews given to a news organization. Nothing here has been adjudicated, and a former employee's description of an internal productivity target is not a finding that the target existed, that it was enforced, or that any patient was injured because of it.
What LifeMD Says
LifeMD's position is a flat denial. Schreiber, the chief executive, disputed the premise that the company puts volume ahead of safety and rejected the comparison to a pill mill. The company has not been charged with anything, has not been found liable, and operates a licensed affiliated medical group across all 50 states.The company's broader defense rests on a point that is legally accurate: asynchronous care, in which a clinician reviews a written intake without a live video visit, is a recognized and lawful way to practice in most states, and it is the mechanism that lets telehealth reach patients who cannot easily get to an office. LifeMD's position is that its affiliated clinicians keep full professional discretion — they can order labs, require a video consultation, or decline to prescribe whenever they judge it appropriate — and that a corporate throughput figure, even if one existed, would not override an individual clinician's judgment.
That defense and the allegations are not quite arguing about the same thing, which is worth naming plainly. Nobody disputes that asynchronous review is lawful. The contested question is whether a workload target can become so tight that the discretion a clinician nominally holds stops being usable in practice. And a separate question sits underneath both: whether any specific patient was harmed. That one would require individual medical evidence, and no such finding exists here. Reporting that raises the first question does not answer the third.
How the Platform Is Built, and Why Speed Pays
To read the allegations fairly you need to understand what LifeMD sells, because the business model is what makes review speed a financial variable rather than a neutral operational detail.The company runs a vertically integrated stack: a consumer-facing intake portal that collects the questionnaire and payment details, an affiliated medical group licensed across all 50 states that reviews those intakes and writes prescriptions, an in-house pharmacy operation that fills and ships, and an administrative layer handling insurance prior authorizations and logistics. Very little of the chain is outsourced, which is why the company's gross margin reached roughly 89% in the second quarter of 2026, up about 280 basis points year over year.
The revenue, though, is not primarily transactional. Roughly 84% of LifeMD's revenue comes from recurring subscriptions rather than one-off visits, and the company reported about 356,000 active subscribers at the end of the second quarter of 2026, up 20% year over year, with roughly 108,000 of those in the weight management program. In a subscription business, the initial clinical review is the gate to a recurring monthly relationship. Every intake that clears becomes a subscriber; every intake that stalls does not.
That is the structural point the reporting raises, and it is not unique to LifeMD. When the clinical review sits directly on the conversion funnel, the incentive gradient runs toward approval and toward speed. Pointing that out is not the same as proving anyone acted on it — but it explains why the specific number in the allegations, 25 files an hour, landed the way it did.
Where the Law Would Actually Bite
If these allegations ever produce consequences, the likeliest route is not a class action. It is professional licensing law, and it runs through two doctrines most readers have never heard of.The Clinician-Patient Relationship Standard
Nearly every state requires a valid clinician-patient relationship before a prescription drug can be written. In practice that means taking an adequate medical history, obtaining informed consent, and reaching a documented judgment that the drug is appropriate for this person. States relaxed a good deal of this during the COVID-19 emergency to enable remote care; much of the post-pandemic rulemaking has been tightening it back up, with increasing emphasis on documented history-taking and an articulable diagnostic basis. Counseling obligations sit here too — patients are supposed to be told about risks such as gastroparesis, acute kidney injury, and the thyroid C-cell tumor warning these drugs carry. Whether that can be done properly inside a two-minute window is exactly the question a licensing board would ask, and boards regulate the individual clinician's license, not the platform's marketing.Corporate Practice of Medicine
The second doctrine is the more interesting one. Many states bar non-physician corporations from practicing medicine or from directing the clinical judgment of licensed professionals — the reason telehealth companies operate through a nominally independent "affiliated medical group" in the first place. The doctrine exists precisely to stop business considerations from overriding medical ones.A corporate throughput quota is close to the center of what that rule contemplates. If a company sets a case-per-hour target and attaches consequences to missing it, a regulator could characterize that as the corporation directing clinical judgment, whatever the paperwork says about clinician autonomy. This is why the specific allegation matters more than it might appear: the claim is not that a doctor made a bad call, it is that a corporation set the clock. No state board has announced an inquiry into LifeMD, and the structure the company describes — independent clinicians retaining discretion — is the standard defense to exactly this theory.
What Regulators Have Done to Other Telehealth Companies
LifeMD has not been sued or sanctioned over any of this. But two recent federal actions against other GLP-1 telehealth companies show what enforcement in this sector actually looks like, and both are worth knowing because neither is about prescribing quality — they are about money and data.In July 2025 the FTC sued the telemedicine firm NextMed over its GLP-1 weight-loss programs, alleging misleading pricing, unsubstantiated weight-loss claims, fake testimonials, distorted consumer reviews, and a failure to get informed consent before recurring charges. Monthly fees of roughly $138 to $188 did not, the FTC said, actually include the drugs, the required labs, or the provider consultations. The Commission approved a final order in December 2025 requiring a $150,000 payment expected to fund consumer refunds, plus substantiation requirements going forward.
Then on July 29, 2026 — nine days after the LifeMD reporting — the FTC, joined by the State of Utah and Los Angeles County, sued Hims & Hers Health in the Northern District of California. The complaint alleges the company shared sensitive health information with advertising platforms including Meta and Snap while marketing itself as private, charged customers for prescriptions before provider consultations, and made subscriptions hard to cancel. The claims run under Section 5 of the FTC Act and the Restore Online Shoppers' Confidence Act. Hims & Hers denies wrongdoing and the case is unresolved.
Neither action involves LifeMD, and neither alleges the kind of prescribing-pace conduct described in the LifeMD reporting. What they establish is the enforcement pattern: the FTC reaches billing, cancellation, advertising claims, and data handling. Clinical adequacy is largely left to state medical boards. A reader trying to guess where LifeMD's exposure sits should weight that division accordingly.
Why Novo Nordisk Keeps Coming Up
Novo Nordisk is not accused of the prescribing conduct. It features in the story because of a commercial relationship that gives the allegations wider significance for the industry.Since 2025, LifeMD's collaboration with Novo Nordisk has expanded from an integration with the drugmaker's NovoCare Pharmacy into a broader commercial arrangement covering injectable and oral Wegovy and Ozempic, and LifeMD is listed as a telehealth provider on both the NovoCare and Wegovy websites. On March 31, 2026, LifeMD announced it was offering Novo Nordisk's multi-month Wegovy subscription program, alongside other telehealth partners, with fixed monthly pricing for eligible self-pay patients.
The arrangement is not exclusive to Novo Nordisk. In March 2025 LifeMD integrated with Gifthealth, the pharmacy provider behind Eli Lilly's LillyDirect self-pay channel, to ship single-dose Zepbound vials to eligible patients — the same move Teladoc made around the same time as restrictions on compounded copies tightened.
The published cash-pay prices show what these arrangements are for. Wegovy starter doses have been offered at $199 a month for a new patient's first fills, Ozempic through NovoCare Pharmacy has run between roughly $199 and $499 a month depending on dose and patient status, and the oral Wegovy pill launched at an introductory $149 a month after its FDA approval in late 2025, with increases announced for higher maintenance doses from April 15, 2026. Verify current pricing with the platform before relying on any of these figures; cash-pay GLP-1 prices have moved repeatedly.
That is the reason a story about one company's internal workflow drew industry-wide attention. Facing formulary exclusions and coverage fights with pharmacy benefit managers, the manufacturers have been building direct cash-pay channels that route patients through named telehealth partners — and naming a partner is a form of vouching for it. Experts quoted in the reporting argue the broader GLP-1 telehealth sector is loosely regulated and has been boosted by the manufacturers themselves. The reputational exposure runs both directions along that channel.
The Wider Regulatory Squeeze on GLP-1 Telehealth
The LifeMD allegations landed in the middle of an escalating federal crackdown on how GLP-1 drugs are marketed and sold online. That crackdown is aimed at a different problem — compounded copies of semaglutide and tirzepatide, and the marketing claims made for them — but it is the backdrop against which the prescribing allegations are being read.• September 2025 — The FDA sends warning letters to more than 50 compounders and manufacturers over misleading claims about compounded GLP-1 products.
• March 3, 2026 — The FDA issues warning letters to 30 telehealth companies over false or misleading claims about compounded semaglutide and tirzepatide, including representations that compounded versions are the same as the FDA-approved drugs.
• June 16, 2026 — The FDA issues a further 25 warning letters on the same theme.
• 2026 — The FDA moves to take semaglutide, tirzepatide, and liraglutide off the list of drugs that outsourcing facilities may compound, which would close the large-scale compounding pipeline.
No FDA warning letter to LifeMD has been identified in this enforcement wave, and the agency's letters concern marketing claims rather than the prescribing-pace allegations described above. The two threads are related only in that both concern how quickly and how loosely a fast-growing online market has been dispensing these drugs. Separately, LifeMD told investors on August 5, 2026 that roughly 95% of its new weight-management patients now start on branded GLP-1 therapies and that it is effectively at the end of its transition away from compounded GLP-1 medications.
LifeMD's Other Litigation, and Why It Is Not This
Search results for "LifeMD investigation" are dominated by two matters that have nothing to do with patient safety. Keeping them straight matters, because they are frequently presented as though they were the same story.The first is a securities class action captioned Johnston v. LifeMD, Inc., filed August 27, 2025 in the U.S. District Court for the Eastern District of New York. Investors allege the company made materially false or misleading statements about its 2025 outlook, in particular by raising full-year guidance in May 2025 without properly accounting for rising customer-acquisition costs in its RexMD segment. LifeMD cut that guidance on August 5, 2025, and the stock fell roughly 45% the next day. Those are allegations; the company has not been found liable. That case concerns disclosures to shareholders, not the care any patient received.
The second is a privacy case that is already over. In W.M.F. & Matthew Marden v. LifeMD, Inc., filed in the District Court of Clark County, Nevada, users alleged that tracking technologies on LifeMD's websites, including its RexMD service, disclosed identifiable health information to third parties such as Meta, Google, and TikTok. The parties settled without any admission of wrongdoing, providing $10 in cash or a $25 voucher per class member, and the court granted final approval on September 30, 2025 and dismissed the case with prejudice. The claim window has closed. If you want to see what an open case of that type looks like, we cover a comparable telehealth tracking-pixel settlement in our report on the Call-On-Doc pixel tracking settlement, which is still accepting claims.
Two older items also circulate in write-ups of the company, and both are routinely presented without their endings. In April 2021 a securities class action, Owens v. LifeMD, Inc., was filed in the Southern District of New York, alleging among other things that the company had not disclosed that several executives were previously associated with Redwood Scientific Technologies, an entity the FTC had pursued over auto-shipping and telemarketing practices. That case was voluntarily dismissed on May 18, 2021, about a month after it was filed. Its allegations were never tested, and citing them as established history is wrong.
Separately, in November 2025 LifeMD postponed its third-quarter earnings release after identifying corrections to how it had recognized revenue across 2023, 2024, and the first half of 2025 — a cumulative effect of roughly $4.6 million, or about 1.4% of the revenue reported over those periods. The company characterized this as a revision rather than a restatement and said it did not materially affect cash flow or performance against guidance. It is a real governance data point and it plainly raised market sensitivity going into 2026, but it is an accounting matter, not a patient-safety one.
What This Means If You Get GLP-1 Drugs Online
There is no action to take against LifeMD, because there is no case for patients to join. What the reporting does offer is a set of questions worth asking of any telehealth platform prescribing these medications.• Did a licensed clinician actually review your history, or did an intake form alone produce the prescription?
• Were you screened for other medical conditions, for medications that interact, and for a history of disordered eating?
• If you report a side effect, does it reach a clinician, and how quickly?
• Are dose escalations reviewed individually, or applied on a schedule?
• Is the medication you are receiving the FDA-approved branded drug or a compounded version, and do you know which?
If you are taking a GLP-1 medication, do not stop on the strength of a news story. Raise concerns with a licensed clinician. If you have a severe or persistent reaction, seek medical care and consider reporting it to the FDA's MedWatch program, which is how adverse events enter the federal safety data. Keep your prescription records, visit notes, and platform messages.
Patients who allege they were physically injured by a GLP-1 drug are in a different posture entirely, and their claims run against the manufacturers rather than a telehealth prescriber. Those cases are consolidated in federal multidistrict litigation, and we track their status in our GLP-1 MDL 3094 update for gastrointestinal injuries and our report on Ozempic eye problems and vision loss claims. Neither has a settlement or a claim form.
What Happens Next
Three things would change the picture, and none of them has happened yet.A regulator could act. State medical boards license the clinicians who write these prescriptions and are the bodies most directly positioned to examine supervision and screening standards, while the FDA and the FTC have both been active on GLP-1 marketing. No public action against LifeMD on these allegations has been announced.
The employment suits could produce documents. The two cases brought by former senior leaders are the only sworn allegations in the story. If either reaches discovery or a public filing stage, internal targets and communications would become testable rather than described secondhand.
Plaintiffs' firms could file. Reporting of this kind sometimes precedes consumer litigation, typically framed as a claim that patients paid for a level of medical care they did not receive. Nothing of that sort has been filed against LifeMD as of this writing. We will update this page if it is.
Frequently Asked Questions
Is there a class action lawsuit against LifeMD over GLP-1 prescribing?No consumer class action over LifeMD's GLP-1 prescribing practices has been identified. The allegations reported in July 2026 come from former employees interviewed by STAT and from two lawsuits filed by former senior leaders of the company, which are employment disputes rather than patient class actions. There is no certified class, no settlement, and no claim form. LifeMD denies the allegations and has not been found liable by any court.
What exactly did former LifeMD employees allege?
According to STAT's July 20, 2026 report, five former employees said clinicians were pushed to work faster than was clinically responsible. Two of them said providers were at times expected to review the cases of 25 people per hour, based only on intake forms patients filled out themselves, which works out to roughly two minutes per case. Former employees also said providers were discouraged from asking questions they considered medically relevant so as not to delay care, and that patient messages routed through medical assistants created delays in responding to reported side effects. These are unproven allegations.
What has LifeMD said in response?
LifeMD strenuously denies the allegations. Its chief executive told STAT that the company's objective has not been to run a pill mill and that it has taken the opposite position. No court or regulator has made any finding against LifeMD on these allegations.
Is Novo Nordisk part of these allegations?
Novo Nordisk is not accused of the prescribing conduct. It appears in the story because it has a commercial relationship with LifeMD: LifeMD is listed as a telehealth provider on Novo Nordisk's NovoCare and Wegovy websites, and in March 2026 LifeMD was one of several telehealth companies offering Novo Nordisk's multi-month Wegovy subscription program. That relationship is why the allegations drew industry-wide attention.
Has the FDA taken action against LifeMD?
No FDA warning letter to LifeMD has been identified. The FDA has been active against the wider GLP-1 telehealth sector, sending warning letters to 30 telehealth companies on March 3, 2026 and another 25 in June 2026 over false or misleading marketing of compounded semaglutide and tirzepatide. Those actions targeted marketing claims about compounded drugs, not the prescribing-pace allegations described in this article.
What should I do if I take a GLP-1 drug prescribed through a telehealth service?
Keep taking a prescribed medication only under the direction of a clinician, and raise any concerns with a licensed medical professional rather than stopping on your own. If you experience severe or persistent side effects, seek medical care and report the event to the FDA's MedWatch program. Save your prescription records, visit notes, and messages with the platform. This page is informational and is not medical or legal advice.
Could a state medical board act on these allegations?
That is the likeliest route if anything comes of them, though no state board has announced an inquiry into LifeMD. Two doctrines are relevant. Most states require a valid clinician-patient relationship before a prescription drug is written, meaning an adequate medical history, informed consent, and a documented judgment that the drug is appropriate. Separately, corporate practice of medicine rules in many states bar non-physician corporations from directing the clinical judgment of licensed professionals, which is why telehealth companies operate through affiliated medical groups. A corporate case-per-hour target could in principle be characterized as directing clinical judgment. None of this has been alleged by any regulator against LifeMD.
Has the FTC sued other GLP-1 telehealth companies?
Yes, though not LifeMD. The FTC sued NextMed in July 2025 over its GLP-1 weight-loss programs, alleging misleading pricing, unsubstantiated weight-loss claims, fake testimonials and consent failures on recurring charges, and approved a final order in December 2025 requiring a $150,000 payment expected to fund refunds. On July 29, 2026 the FTC, with the State of Utah and Los Angeles County, sued Hims & Hers Health in the Northern District of California over health-data sharing with advertising platforms and subscription billing and cancellation practices. Hims & Hers denies wrongdoing and that case is unresolved. Both actions concern billing, advertising and data handling rather than the adequacy of clinical review.
Sources
• STAT — "LifeMD, a popular telehealth firm, put profits over patient safety, ex-workers say," July 20, 2026 — the originating investigation, including the former employees' accounts and the company's denial• U.S. Food & Drug Administration — Warning letters to 30 telehealth companies, March 3, 2026
• U.S. Food & Drug Administration — Guidance for telehealth companies promoting compounded drugs
• U.S. Food & Drug Administration — Semaglutide safety information for patients and providers
• Federal Trade Commission — Action against NextMed over GLP-1 weight-loss program marketing, July 2025
• Federal Trade Commission — Final order against NextMed, December 2025
• CNBC — FTC and states sue Hims & Hers over data and billing practices, July 29, 2026
• LifeMD press release — Novo Nordisk Wegovy telehealth subscription program, March 31, 2026
• LifeMD press release — LillyDirect pharmacy integration for Zepbound, March 6, 2025
• LifeMD — Second Quarter 2026 Results, August 5, 2026 — branded-GLP-1 mix and the end of the compounded transition
• SEC EDGAR — LifeMD, Inc. periodic filings — the company's own legal-proceedings disclosures
• Official settlement website — Marden v. LifeMD, Inc. — the closed Nevada privacy settlement, court documents and final approval
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
For more class actions keep scrolling below.
Status
Allegations reported — no class action filed over prescribing
Company
LifeMD, Inc. (NASDAQ: LFMD), operator of LifeMD and RexMD
What Is Alleged
Clinicians pushed to review up to 25 GLP-1 patient cases per hour with limited screening and follow-up — denied by the company
Source of Allegations
Five former employees interviewed by STAT, plus two lawsuits filed by former senior leaders (reported July 20, 2026)
Separate Litigation
Johnston v. LifeMD, Inc., U.S. District Court, Eastern District of New York (securities case — investor disclosures, not patient care)
Can Patients Claim?
No — no certified class, no settlement, no claim form
Official Website
FDA — Telehealth & Compounded Drugs
